AU2017328913B2 - Macrophage-based therapy for use in the treatment of liver injury - Google Patents

Macrophage-based therapy for use in the treatment of liver injury Download PDF

Info

Publication number
AU2017328913B2
AU2017328913B2 AU2017328913A AU2017328913A AU2017328913B2 AU 2017328913 B2 AU2017328913 B2 AU 2017328913B2 AU 2017328913 A AU2017328913 A AU 2017328913A AU 2017328913 A AU2017328913 A AU 2017328913A AU 2017328913 B2 AU2017328913 B2 AU 2017328913B2
Authority
AU
Australia
Prior art keywords
macrophages
cells
liver
bmdms
alternatively
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017328913A
Other languages
English (en)
Other versions
AU2017328913A1 (en
Inventor
Stuart Forbes
Lesley FORRESTER
Philip Starkey LEWIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Original Assignee
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1615923.8A external-priority patent/GB201615923D0/en
Priority claimed from GBGB1707183.8A external-priority patent/GB201707183D0/en
Application filed by University of Edinburgh filed Critical University of Edinburgh
Publication of AU2017328913A1 publication Critical patent/AU2017328913A1/en
Application granted granted Critical
Publication of AU2017328913B2 publication Critical patent/AU2017328913B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2313—Interleukin-13 (IL-13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017328913A 2016-09-19 2017-09-18 Macrophage-based therapy for use in the treatment of liver injury Active AU2017328913B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1615923.8A GB201615923D0 (en) 2016-09-19 2016-09-19 Macrophage-based therapy
GB1615923.8 2016-09-19
GB1707183.8 2017-05-05
GBGB1707183.8A GB201707183D0 (en) 2017-05-05 2017-05-05 Macrophage-based therapy
PCT/GB2017/052769 WO2018051136A1 (en) 2016-09-19 2017-09-18 Macrophage-based therapy for use in the treatment of liver injury

Publications (2)

Publication Number Publication Date
AU2017328913A1 AU2017328913A1 (en) 2019-02-28
AU2017328913B2 true AU2017328913B2 (en) 2023-08-17

Family

ID=60083347

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017328913A Active AU2017328913B2 (en) 2016-09-19 2017-09-18 Macrophage-based therapy for use in the treatment of liver injury

Country Status (6)

Country Link
US (1) US11285174B2 (enExample)
EP (2) EP3515460B1 (enExample)
JP (1) JP7115755B2 (enExample)
CN (1) CN109789163A (enExample)
AU (1) AU2017328913B2 (enExample)
WO (1) WO2018051136A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2896548T3 (es) 2015-10-30 2022-02-24 Biolamina Ab Métodos de producción de hepatocitos
GB2572005A (en) 2018-03-16 2019-09-18 Univ Court Univ Of Edinburgh Macrophage-based therapy
CN112955161B (zh) * 2018-09-06 2024-12-17 泰克年研究发展基金会公司 通过活化细胞修复组织
GB202007905D0 (en) * 2020-05-27 2020-07-08 Univ Edinburgh Cryopressing macrophages
CN111933006B (zh) * 2020-07-30 2022-06-03 四川大学华西医院 一种模拟巨噬细胞改善小鼠急性肾损伤实验的方法及系统
CN114622017A (zh) * 2020-12-14 2022-06-14 中山大学孙逸仙纪念医院 Isg15、isg15诱导的巨噬细胞及其分泌物在肿瘤治疗中的应用
WO2023075623A1 (en) * 2021-10-26 2023-05-04 Ineb (Instituto Nacional De Engenharia Biomédica) Macrophage phenoypes for use in the treatment of intravertebral discs
CN115212320B (zh) * 2022-08-04 2025-07-15 温州医科大学慈溪生物医药研究院 一种双靶向脂质体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103977029A (zh) * 2014-04-11 2014-08-13 中国人民解放军第四军医大学 经典激活的巨噬细胞在治疗肝纤维化的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10724003B2 (en) * 2015-01-16 2020-07-28 Agency For Science, Technology And Research Method of differentiating human pluripotent stem cells into primitive macrophages

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103977029A (zh) * 2014-04-11 2014-08-13 中国人民解放军第四军医大学 经典激活的巨噬细胞在治疗肝纤维化的应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANTONIO SICA, ALBERTO MANTOVANI: "Macrophage plasticity and polarization: in vivo veritas", JOURNAL OF CLINICAL INVESTIGATION, vol. 122, no. 3, 1 March 2012 (2012-03-01), pages 787 - 795, XP055111479, ISSN: 00219738, DOI: 10.1172/JCI59643 *
GORDON SIAMON: "Alternative activation of macrophages.", NATURE REVIEWS IMMUNOLOGY, NATURE PUBLISHING GROUP UK, LONDON, vol. 3, no. 1, 1 January 2003 (2003-01-01), London, pages 23 - 35, XP002565133, ISSN: 1474-1733, DOI: 10.1038/nri978 *
HOLT MICHAEL P ET AL: December 2008 (2008-12-01), pages 24PP, XP002776701, Retrieved from the Internet [retrieved on 20171211], DOI: 10.1189/jlb.0308173 *
MURRAY P J, ALLEN J E, BISWAS S K, FISHER E A, GILROY D W, GOERDT S, GORDON S, HAMILTON J A, IVASHKIV L B, LAWRENCE T, LOCATI M, M: "Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines", IMMUNITY, vol. 41, no. 1, 17 July 2014 (2014-07-17), pages 14 - 20, XP002776702, DOI: 10.1016/j.immuni.2014.06.008 *
NISHIDA, M. ; OKUMURA, Y. ; FUJIMOTO, S.I. ; SHIRAISHI, I. ; ITOI, T. ; HAMAOKA, K.: "Adoptive transfer of macrophages ameliorates renal fibrosis in mice", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 332, no. 1, 24 June 2005 (2005-06-24), Amsterdam NL , pages 11 - 16, XP027229822, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2005.04.083 *
SIAMON GORDON, FERNANDO O MARTINEZ: "Alternative activation of macrophages: mechanism and functions.", IMMUNITY, CELL PRESS, UNITED STATES, vol. 32, no. 5, 28 May 2010 (2010-05-28), United States , pages 593 - 604, XP002776700, ISSN: 1097-4180, DOI: 0.1016/j.immuni.2010.05.007 *
THOMAS J A, POPE C, WOJTACHA D, ROBSON A J, GORDON-WALKER T T, HARTLAND S, RAMACHANDRAN P, VAN DEEMTER M, HUME D A, IREDALE J P, F: "Macrophage Therapy for Murine Liver Fibrosis Recruits Host Effector Cells Improving Fibrosis, Regeneration, and Function", HEPATOLOGY, vol. 53, no. 6, 1 June 2011 (2011-06-01), pages 2003 - 2015, XP002776703, DOI: 10.1002/hep.24315 *
ZHUANG LIHUI; POUND JOHN D.; WILLEMS JORINE J.L.P.; TAYLOR A. HELEN; FORRESTER LESLEY M.; GREGORY CHRISTOPHER D.: "Pure populations of murine macrophages from cultured embryonic stem cells. Application to studies of chemotaxis and apoptotic cell clearance", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM., NL, vol. 385, no. 1, 1 January 1900 (1900-01-01), NL , pages 1 - 14, XP028940449, ISSN: 0022-1759, DOI: 10.1016/j.jim.2012.06.008 *

Also Published As

Publication number Publication date
EP3515460B1 (en) 2025-09-17
JP2019532634A (ja) 2019-11-14
US11285174B2 (en) 2022-03-29
CN109789163A (zh) 2019-05-21
WO2018051136A9 (en) 2019-02-07
AU2017328913A1 (en) 2019-02-28
JP7115755B2 (ja) 2022-08-09
EP4640237A2 (en) 2025-10-29
EP3515460A1 (en) 2019-07-31
US20190240256A1 (en) 2019-08-08
WO2018051136A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
AU2017328913B2 (en) Macrophage-based therapy for use in the treatment of liver injury
Mauro et al. M1 and M2 macrophage recruitment during tendon regeneration induced by amniotic epithelial cell allotransplantation in ovine
Guan et al. Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes
JP2008526762A (ja) 組織再生および創傷治癒のための脂肪由来幹細胞
KR20170116219A (ko) 조직 복구 및 재생을 위한 세포 증식 방법 및 약제학적 제제
TWI820753B (zh) 使用人類間葉幹細胞以實現細胞性及體液性免疫的方法
JP6622189B2 (ja) 疼痛及び／又は線維症の調節において脂肪組織由来細胞を使用する方法
JP2013528230A (ja) ノーオプション重症虚血肢（ｃｌｉ）を処置するための組成物および方法
CN107988141A (zh) 肝纤维化模型及其构建方法与应用
US20240252541A1 (en) Methods of cell therapies
Jin et al. Hepatocyte growth factor promotes liver regeneration induced by transfusion of bone marrow mononuclear cells in a murine acute liver failure model
CA3049856C (en) Neutrophil activation regulator
US20190201455A1 (en) Prophylactic or therapeutic agent for organ fibrosis
JP2016505249A (ja) 多分化能細胞を作製する方法
CN107970435B (zh) 联合诱导内源Lgr5+肝脏干细胞增多的方法及应用
Ma et al. Endothelial bioreactor system ameliorates multiple organ dysfunction in septic rats
US20240189364A1 (en) Villi stromal cells compositions and uses thereof
Janmohamed Investigating the immunomodulatory role of mesenchymal stromal cells in primary sclerosing cholangitis
Seifert The Inflammatory Response Initiated by the Spleen to Ischemic Stroke
Alfaifi Cell therapy for acute liver injury-in vivo efficacy of mesenchymal stromal cells in toxic and immune-mediated murine hepatitis
CN107982518A (zh) 一种Lgr5阳性肝脏干细胞诱导方法及其检测应用
Norman Jr Origin and maturation of the pulmonary lymphatic endothelium
Ghita Adipose derived stromal vascular fraction: therapeutic potential of renal artery administration in renal ischaemia reperfusion injury
Clark Investigation into the action of mesenchymal stromal cells in renal ischaemia reperfusion injury
Mohamed et al. COMPARATIVE STUDY BETWEEN THE EFFECTS OF HUMAN CD34 AND RAT BONE MARROW MESENCHYMAL STEM CELLS ON AMELIORATION OF CCL4 INDUCED LIVER FIBROSIS.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)